GINA PAGOTTO: Open Payments
NPI 1689991283 · BRYN MAWR, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,016 in 82 payments from 30 companies in 2025. Trend: 2023 $2,690 · 2024 $2,358 · 2025 $2,016
Food & beverage: $1,974Education: $42
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $296 |
| US Oncology Corporate, Inc. | 2 | $272 |
| AstraZeneca Pharmaceuticals LP | 7 | $158 |
| Astellas Pharma US Inc | 7 | $127 |
| Ipsen Biopharmaceuticals, Inc | 4 | $100 |
| Novartis Pharmaceuticals Corporation | 5 | $97 |
| Celgene Corporation | 4 | $96 |
| GlaxoSmithKline, LLC. | 3 | $71 |
| GENZYME CORPORATION | 2 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
Products named: IMBRUVICA, Somatuline Depot, REBLOZYL, Venclexta, IMFINZI, SARCLISA, ENHERTU, Vyloy.
Industry payments across PA — which companies pay providers there.
